The Life Sciences team advised Sage Therapeutics on its public offering totaling approximately $575 million in gross proceeds from the sale of 3,506,098 shares of common stock at a price of $164.00 per share. The underwriters also have a 30-day option to purchase up to an additional 525,914 shares of common stock at the offering price.

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders.

The Goodwin team was led by partners Mitchell Bloom and Laurie Burlingame and included partners Janet Andolina, Martin Carmichael, Catherine McCarty and Ettore Santucci; counsel Stephanie Philbin; and associates Jesse Nevarez, Gabriela Morales-Rivera, Humza Bokhari and Olivia Uitto.

For more information on the offering, please read the press release.